Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Anesthesiology & Pain Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Emergency Medicine Urology Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Tumor

Part of Cancer

19 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for tumor

37 trials tracked for tumor: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 62 citations.

37Trials tracked

4Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 4 1 Phase 3 3 Phase 2 16 Phase 1 13 Other / NA 4

Phase 3 Additive Homeopathy in Cancer Patients Completed · 62 cited
Phase 4 Dexmedetomidine and Propofol for Pediatric MRI Sedation Completed
Phase 3 Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer Completed
Phase 3 A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine Completed
Phase 2 A Study of Atezolizumab in Advanced Solid Tumors Completed
Phase 2 Oral Topotecan to Treat Recurrent or Persistent Solid Tumors Completed

Show 31 more trials

Phase 2 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Completed
Phase 2 A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors Completed
Phase 2 Study of BMS-986158 in Subjects With Select Advanced Cancers Completed
Phase 2 Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Completed
Phase 2 A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer Completed
Phase 2 Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors Completed
Phase 2 A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors Completed
Phase 2 A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors Completed
Phase 2 Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours Completed
Phase 2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma Completed
Phase 2 NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) Completed
Phase 2 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Completed
Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer Completed
Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer Completed
Phase 1 A Study of IMC-TR1 in Participants With Advanced Solid Tumors Completed
Phase 1 MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies Completed
Phase 1 A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) Completed
Phase 1 NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors Completed
Phase 1 A Study of IMC-A12 in Advanced Solid Tumors Completed
Phase 1 Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults Completed
Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Completed
Phase 1 A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) Completed
Phase 1 A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED) Completed
Phase 1 Phase 1 Study of E7090 in Subjects With Solid Tumor Completed
Phase 1 A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors Completed
Phase 1 Study of Dasatinib (BMS-354825) in Patients With Solid Tumors Completed
Phase 1 Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors Completed
N/A The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy Completed
N/A Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Completed
N/A High-density EEG in Neurological Disorders Completed
N/A MaxAn Post Market Surveillance Validation Completed

Showing the 37 most-cited and recently-updated of 37 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Tumor: what the trials found

Established evidence for tumor management includes the use of propofol ², Denosumab ⁵, and Lenvatinib [7, 13]. Regarding pain management in this population, Tapentadol Extended Release was evaluated against Morphine; during the titration phase, average daily pain intensity scores were reported as 6.315, 5.324, and 4.021 for Tapentadol across three groups, compared to 6.162, 4.906, and 3.669 for Morphine ⁴.

In a study of additive classical homeopathy, there was no statistically significant difference in EORTC-QLQ-C30 scores (51.2 vs 46.6, p=0.397), but survival outcomes were significantly different across the groups (23; 11; 7, p=0.02) ³. Lenvatinib was also evaluated in a cohort study where serum biomarker levels showed no significant change from baseline to worst post-baseline scores (p=0.20359) ¹³.

Recent results — preliminary, needs further review

* Ezabenlimab was evaluated in a Phase 2 trial ¹. * E7090 was evaluated in a Phase 1 trial ²¹.

For the clinician treating this condition

Tapentadol Extended Release and Morphine were both utilized for pain management, with specific mean daily intensity scores recorded during titration ⁴.
Lenvatinib has been studied in multiple contexts, including evaluations of performance status shifts and serum biomarker levels [7, 13].

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

‹ Prev 1 2